Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype E Bresin, E Rurali, J Caprioli, P Sanchez-Corral, V Fremeaux-Bacchi, ... Journal of the American Society of Nephrology 24 (3), 475-486, 2013 | 416 | 2013 |
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy M Noris, M Galbusera, S Gastoldi, P Macor, F Banterla, E Bresin, ... Blood, The Journal of the American Society of Hematology 124 (11), 1715-1726, 2014 | 331 | 2014 |
Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome P Iatropoulos, M Noris, C Mele, R Piras, E Valoti, E Bresin, M Curreri, ... Molecular immunology 71, 131-142, 2016 | 169 | 2016 |
Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome EC Schramm, LT Roumenina, T Rybkine, S Chauvet, P Vieira-Martins, ... Blood, The Journal of the American Society of Hematology 125 (15), 2359-2369, 2015 | 130 | 2015 |
A novel atypical hemolytic uremic syndrome–associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H–dependent complement regulation E Valoti, M Alberti, A Tortajada, J Garcia-Fernandez, S Gastoldi, L Besso, ... Journal of the American Society of Nephrology 26 (1), 209-219, 2015 | 123 | 2015 |
Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/immune complex–mediated membranoproliferative GN P Iatropoulos, E Daina, M Curreri, R Piras, E Valoti, C Mele, E Bresin, ... Journal of the American Society of Nephrology 29 (1), 283-294, 2018 | 121 | 2018 |
Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature L Manenti, E Gnappi, A Vaglio, L Allegri, M Noris, E Bresin, FP Pilato, ... Nephrology Dialysis Transplantation 28 (9), 2246-2259, 2013 | 85 | 2013 |
An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome M Galbusera, M Noris, S Gastoldi, E Bresin, C Mele, M Breno, ... American Journal of Kidney Diseases 74 (1), 56-72, 2019 | 75 | 2019 |
Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome C Mele, M Lemaire, P Iatropoulos, R Piras, E Bresin, S Bettoni, D Bick, ... Clinical Journal of the American Society of Nephrology 10 (6), 1011-1019, 2015 | 58 | 2015 |
Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations M Alberti, E Valoti, R Piras, E Bresin, M Galbusera, C Tripodo, F Thaiss, ... American Journal of Transplantation 13 (8), 2201-2206, 2013 | 52 | 2013 |
Unraveling the molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and IC-MPGN R Donadelli, P Pulieri, R Piras, P Iatropoulos, E Valoti, A Benigni, ... Frontiers in immunology 9, 2329, 2018 | 43 | 2018 |
Rare functional variants in complement genes and anti-FH autoantibodies-associated aHUS E Valoti, M Alberti, P Iatropoulos, R Piras, C Mele, M Breno, A Cremaschi, ... Frontiers in Immunology 10, 853, 2019 | 38 | 2019 |
European Working Party on Complement Genetics in Renal Diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype E Bresin, E Rurali, J Caprioli, P Sanchez-Corral, V Fremeaux-Bacchi, ... J Am Soc Nephrol 24 (3), 475-486, 2013 | 34 | 2013 |
Registry of Membranoproliferative Glomerulonephritis/C3 Glomerulopathy; Nastasi: Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/immune … P Iatropoulos, E Daina, M Curreri, R Piras, E Valoti, C Mele, E Bresin, ... J Am Soc Nephrol 29 (1), 283-94, 2018 | 22 | 2018 |
CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis R Piras, M Breno, E Valoti, M Alberti, P Iatropoulos, C Mele, E Bresin, ... Frontiers in genetics 12, 670727, 2021 | 16 | 2021 |
Impact of a complement factor H gene variant on renal dysfunction, cardiovascular events, and response to ACE inhibitor therapy in type 2 diabetes E Valoti, M Noris, A Perna, E Rurali, G Gherardi, M Breno, ... Frontiers in Genetics 10, 681, 2019 | 11 | 2019 |
More about factor H autoantibodies in membranous nephropathy E Valoti, M Noris, G Remuzzi New England Journal of Medicine 381 (16), 1590-1592, 2019 | 10 | 2019 |
Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a … R Piras, P Iatropoulos, E Bresin, M Todeschini, S Gastoldi, E Valoti, ... Frontiers in Medicine 7, 579418, 2020 | 9 | 2020 |
Posttransplant recurrence of atypical hemolytic uremic syndrome. E Valoti, M Alberti, M Noris Journal of Nephrology 25 (6), 911-917, 2012 | 7 | 2012 |
CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome R Piras, E Valoti, M Alberti, E Bresin, C Mele, M Breno, L Liguori, ... Frontiers in Immunology 13, 1011580, 2023 | 6 | 2023 |